Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

Gene & Cell Therapy: State of the Field (October 2026)

Covers adeno-associated virus (AAV) and lentiviral gene therapy, in vivo CAR-T and stem-cell-derived replacement cells such as islets and dopaminergic neurons, with the evidence as of October 2026. The main takeaway: viral gene addition has clinical precedent in several monogenic diseases, but immune responses, dose-linked toxicity and integration questions still bound the field, while in vivo CAR-T and stem-cell replacement remain at early clinical or preclinical stages.

3,785 words57 sources34 evidence-mapped claims8 benchmarks19 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Adeno-associated virus (AAV) in vivo gene therapy
  6. Capsid engineering and immune evasion
  7. Lentiviral and ex vivo HSPC gene therapy
  8. In vivo CAR-T and CAR engineering
  9. Stem-cell-derived islets
  10. Dopaminergic cell replacement and gene correction
  11. Quantitative benchmarks
  12. Open problems and active debates
  13. Major programs and players
  14. Outlook: what to watch (near term)
  15. Key papers
  16. Glossary

Sample findings

  • In a 2022 meta-analysis of 255 rAAV clinical trials, AAV2 was the most frequently used serotype (reported as 29.8%, n = 72 trials); the abstract does not state the denominator for this percentage.
  • The same meta-analysis reports 20 trials (reported as 8.3%) using engineered capsids; the abstract does not state the denominator.
The full dossier (3,785 words, 57 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.